RxDoctor Payments Data

Thomas McKinley, MD

Internal Medicine · Mount Vernon, OHNPI 1639250830

Payments from drug & device makers

$882in general payments, 2019–2025

Across 53 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$142
  • Amgen$113
  • Novo Nordisk$105
  • AstraZeneca$92
  • Pfizer$87
  • Smith+Nephew$85
  • plus $258 from 11 others

What the payments were for

  • Food & beverage$882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$882 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$136,884
Medicare patients
929
Services billed
2,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$201,196
TrulicityDulaglutide56$109,473
JardianceEmpagliflozin103$109,350
OzempicSemaglutide67$94,778
XareltoRivaroxaban38$50,830
MounjaroTirzepatide39$42,272
JanuviaSitagliptin Phosphate20$32,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$28,385
FarxigaDapagliflozin Propanediol27$26,358
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$18,501
Spiriva RespimatTiotropium Bromide32$16,276
Breo ElliptaFluticasone/Vilanterol31$14,909
Lantus SolostarInsulin Glargine,hum.Rec.Anlog121$13,487
SymbicortBudesonide/Formoterol Fumarate31$12,164
Advair HfaFluticasone Propion/Salmeterol19$11,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$201,196204 claims
Lilly USA, LLCTrulicity, Mounjaro$39$151,74595 claims
Boehringer IngelheimJardiance, Spiriva Respimat$35$125,627135 claims
Novo NordiskOzempic$105$94,77867 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$92$49,01875 claims
GSKTrelegy Ellipta, Breo Ellipta$26$43,29468 claims
AbbVieSynthroid$142$3,80177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Mount Vernon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →